Last Monday, Pfizer and Medivation announced their merger, with Pfizer buying Medivation for $14 billion in cash. Pfizer won out over numerous other bidders, including Celgene, Gilead Sciences, Merck and Sanofi.
GSK deal with Italian Medicines Agency highlights performance-based curative model
GlaxoSmithKline (GSK) has signed a pay-for-performance deal with the Italian Medicines Agency (AIFA) to boost usage of Strimvelis, the pharmaceutical company’s gene therapy treatment developed for ADA-SCID, a rare genetic disorder in children. The key to the contract, however, is that the drug must work. If treatment doesn’t provide a cure, GSK must return a portion of the funds paid by AIFA based on the terms of the agreement.
To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.